News Clinigen buys remaining rights to Novartis cancer drug UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million.
News Better slashes staff in another digital health retreat Company will cut its headcount by 35%, as it waits for an FDA decision on its diabetes DTx.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
